In today’s recent session, 0.48 million shares of the Sage Therapeutics Inc (NASDAQ:SAGE) have been traded, and its beta is 0.91. Most recently the company’s share price was $7.11, and it changed around -$1.37 or -16.10% from the last close, which brings the market valuation of the company to $434.37M. SAGE at last check was trading at a discount to its 52-week high of $28.26, offering almost -297.47% off that amount. The share price’s 52-week low was $5.84, which indicates that the recent value has risen by an impressive 17.86% since then. We note from Sage Therapeutics Inc’s average daily trading volume that its 10-day average is 0.64 million shares, with the 3-month average coming to 662.21K.
Sage Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.95. If we narrow it down even further, the data shows that 0 out of 15 analysts rate the stock as a Sell; another 6 rate it as Overweight. Among the rest, 1 recommended SAGE as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sage Therapeutics Inc (NASDAQ:SAGE) trade information
Instantly SAGE has been showing red trend so far today with a performance of -16.10% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 8.70 on recent trading dayincreased the stock’s daily price by 18.28%. The company’s shares are currently down -67.17% year-to-date, but still down -6.99% over the last five days. On the other hand, Sage Therapeutics Inc (NASDAQ:SAGE) is 2.23% up in the 30-day period. We can see from the shorts that 6.11 million shares have been sold at a short interest cover period of 9.76 day(s).
The consensus price target as assigned by Wall Street analysts is $28, which translates to bulls needing to increase their stock price by 74.61% from its current value. Analyst projections state that SAGE is forecast to be at a low of $9 and a high of $105.
Sage Therapeutics Inc (SAGE) estimates and forecasts
Sage Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -46.42 percent over the past six months and at a 28.95% annual growth rate that is well above the industry average of 17.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -2.28%. Sage Therapeutics Inc earnings are expected to increase by 28.59% in 2024, but the outlook is positive 16.80% per year for the next five years.
SAGE Dividends
Sage Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-12.
Sage Therapeutics Inc (NASDAQ:SAGE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.90% of Sage Therapeutics Inc shares, and 90.28% of them are in the hands of institutional investors. The stock currently has a share float of 102.48%. Sage Therapeutics Inc stock is held by 276.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 10.6696% of the shares, which is about 6.42 million shares worth $69.68 million.
FMR LLC, with 9.6836% or 5.82 million shares worth $63.24 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
